|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2002-8-6
|
|
pubmed:abstractText |
Overexpression of epidermal growth factor receptor (EGF-R) is associated with increased malignant potential and correlates with poor clinical outcome in head and neck cancer. Therefore, inhibition of the EGF-R pathway provides an ideal target for molecular therapy. We examined in vitro and in vivo effects of PKI166, an orally administered EGF-R inhibitor, on 2 human squamous cell carcinoma of the oral cavity cell lines, Tu159 and MDA1986.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0886-4470
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
875-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12162763-Animals,
pubmed-meshheading:12162763-Carcinoma, Squamous Cell,
pubmed-meshheading:12162763-Disease Models, Animal,
pubmed-meshheading:12162763-Dose-Response Relationship, Drug,
pubmed-meshheading:12162763-Gene Targeting,
pubmed-meshheading:12162763-Gene Therapy,
pubmed-meshheading:12162763-Genes, erbB-1,
pubmed-meshheading:12162763-Humans,
pubmed-meshheading:12162763-Male,
pubmed-meshheading:12162763-Mice,
pubmed-meshheading:12162763-Mouth Neoplasms,
pubmed-meshheading:12162763-Receptor, Epidermal Growth Factor,
pubmed-meshheading:12162763-Signal Transduction,
pubmed-meshheading:12162763-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report.
|
|
pubmed:affiliation |
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA. jmyers@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
